To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
The SLC35A1 knockout A2058 cell line, deficient in solute carrier family 35 member A1 that transports nucleotide sugars (CMP-sialic acid) into the Golgi, allows for the investigation of nucleotide sugar transport disruption in melanoma, potentially affecting Golgi glycosylation, sialylation, and glycosylatioN-dependent processes in melanoma cells.
Product Type
KO Cell Lines
Species
Human
Cell Morphology
Epithelial cells, adherent
Passage Ratio
1:2~1:3
Cell Line
A2058
Primary Disease
Melanoma
Lineage
Skin
Specification
Cell Viability
>90%
Sterility Test
The sterility test indicated an absence of microbial growth.
Identity Test
STR identification
Mycoplasma Test
Negative
Virus Test
Negative for HIV, HBV and HCV.
Genetic Stability Testing
We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation
PCR, Sanger Sequencing
Culture Medium
EMEM & FBS & Glutamine
Application
Functional assay
Size
1 M cells/vial*2
Product Format
Frozen
Shipping
Dry ice
Availability Status
Made to order
Handling Notes
Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer
This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.
Transports nucleotide sugars, including CMP-sialic acid, into the Golgi apparatus for glycosylation; defects cause congenital disorder of glycosylation type 2F (CDG2F).